TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company focused on sickle cell disease (SCD), today announced the advancement of two real-world evidence (RWE) initiatives across the Gulf Cooperation Council (GCC) region and the signing of an exclusive distribution agreement in Libya, marking the company’s entry into North Africa.The initiatives are intended to generate additional real-world evidence on the use of Endari® (prescrip